Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 26 results for semaglutide

  1. Semaglutide for managing overweight and obesity (TA875)

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.

  2. Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

  3. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

  4. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

  5. Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)

    NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA910

  6. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic selection

  7. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic selection

  8. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]

    Awaiting development Reference number: GID-TA11414 Expected publication date: TBC

  9. Tirzepatide for managing overweight and obesity (TA1026)

    Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.

  10. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.

  11. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  12. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  13. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  14. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149